US-China Patient Day

On January 7, 2014, President Barack Obama nominated Max Sieben Baucus to be Ambassador of the United States of America to China. The Senate confirmed him on February 6, 2014 and Vice President Joe Biden swore him in on February 21, 2014.

Ambassador Baucus formerly served as the senior United States Senator from Montana. He served in the U.S. Senate from 1978 to 2013, was Montana’s longest serving U.S. Senator, and had the third longest tenure among those serving in the U.S. Senate. Ambassador Baucus was Chairman and Ranking Member of the Senate Committee on Finance, Vice Chairman of the Joint Committee on Taxation, member of the Senate Committee on Agriculture, Nutrition and Forestry, and member of the Joint Select Committee on Deficit Reduction. He was also a member of the Senate Committee on Environment and Public Works and chaired its Subcommittee on Transportation and Infrastructure. Before his election to the U.S. Senate, Ambassador Baucus was a member of the U.S. House of Representatives from 1975 to 1978. He previously served in the Montana House of Representatives from 1973 to 1974.

Ambassador Baucus has extensive experience in international trade. As Chairman of the Senate Committee on Finance, Ambassador Baucus led the passage and enactment of Free Trade Agreements with 11 countries: Australia, Bahrain, Jordan, Chile, Colombia, Morocco, Oman, Panama, Peru, Singapore, and South Korea. He also worked to increase U.S. exports by knocking down trade barriers and led business leaders on trade missions abroad to Germany, Spain, Belgium, Russia, Japan, New Zealand, Brazil, Colombia, and China. During his tenure on the Senate Committee on Finance, Ambassador Baucus was deeply involved in orchestrating congressional approval of permanent normal trade relations with China in 2000 and in facilitating China’s entrance into the World Trade Organization in 2001.

Ambassador Baucus earned a bachelor’s degree and law degree from Stanford University. He is married and has one son and two stepchildren.

Huang Jie-Fu is former Vice Chairman of the Central Committee of Health Care, former Vice Minister of the National Health and Family Planning Commission of the PRC, and a highly recognized liver transplant specialist in China. He is a member of the CPPCC National Committee; Vice Chairman of the CPPCC National Committee of Education, Science, Culture, Health and Sports; President of Chinese Hospital Association; President of China Tobacco Control Association; Dean of Institute for Hospital Management of Tsinghua University; Chief of Department of Liver Surgery in Beijing Xiehe (Union) Hospital; and Director of the National Organ Donation Committee and Organ Transplant Committee. In addition, he is a guest and honorary professor of many leading universities both in China and abroad, and he is an academician of the Royal College of Surgeons of Edinburgh and of Hong Kong Academy of Medicine. Dr. Huang is also a Chinese member of the American Society of Transplantation.

Dennis Simmons is a career Foreign Service Officer and Commercial Diplomat with the U.S. Department of Commerce. Mr. Simmons joined the Department of Commerce’s International Trade Administration in 1997 and became a Foreign Service Officer in 2003. Mr. Simmons is currently assigned to the U.S. Embassy in Beijing, China as the Industry Team Leader for the Automotive, Healthcare and Agribusiness industries. In this capacity, he leads a team of trade promotion and policy specialists to promote and advocate for U.S. firms in these market segments.
Mr. Simmons holds a bachelor’s degree from Stetson University in DeLand, Florida and a master’s degree from the Florida Institute of Technology in Melbourne, Florida. Mr. Simmons is the son of a retired State Department Foreign Service Officer. He speaks Mandarin, Spanish, French, and Russian. Mr. Simmons is married to Foreign Service Specialist Monica Castellanos Simmons and they have two young children and a chocolate Labrador retriever.

Deputy Secretary General of China Hospital Association, Professor (Senior Editor).She has been engaged in health news work for many years. In 1998, she won the China News Award (Column Award). In 2011, she was selected as a member in expert group of All-China Journalists' Association, and served as a judge of the China News awards. A number of her academic theses have been published in the core press journals and hospital management journals. Since 2012, she has been served as Deputy Secretary General of Chinese Hospital Association, leading many research projects, including researches on hospital nursing staff rights protection, violence incidents that injure medical staff in hospital, personnel flow and loss in county hospitals, professionalization and professional training of presidents of Chinese hospitals, medical and health integration of county and village.

Professor Wang Yipeng is the Vice President of the Peking Union Medical College Hospital(PUMCH). He supervises PUMCH’s medical work, and was at one time responsible for implementing the hospital’s information management, education and research work.

Prof. Wang Yipeng is also an expert on orthopedics, chief physician and PhD supervisor.

Between 1989 and 1995, Prof. Wang carried out advanced studies and his Post-Doc research at the University of Kentucky and the University of California’s Irving School of Medicine. Prof. Wang has extensive experience in the national and international academic community. He has served multiple positions for the academic groups and published numerous research papers.

Jun is the Executive Director of the US-China Healthcare Cooperation Program (HCP) at AmCham China since September 1, 2011. The program is a bilateral public-private partnership initiative that focuses on healthcare capacity building and exploring future business opportunities for the US healthcare industry in China.

Before joining AmCham, Jun worked with Novartis and led the China Rural Initiative, developing national business model for non-urban China market, and leading the company’s healthcare education programs in rural China. He has successfully established a model for growth that combines all different types of products from Novartis Group, supported by the educational programs, and leveraging company’s strong local commercial capacity.

Jun has over 15 years experience in healthcare industry. He was a physician by training, and worked as a Urologist in Beijing Friendship Hospital. Prior to Novartis, Jun worked as senior consultant and engagement manager with IMS Health in APAC region for 5 years, developed and managed over fifty projects, focusing on Growth Strategy, Industry Positioning, M&A, and Market Access. Jun also worked with SAI Healthcare, a strategic consulting firm in the US, as the country manager for CHina; and with Zuellig Pharma China as regional commercial manager.

Jun has strong leadership experience and extensive exposure to different markets. During his career with consulting firms, Jun has led different multinational teams to provide consulting services in the US, China, ASEAN countries and Taiwan. He has helped to develop the strategic consulting business for IMS in China and Southeast Asia from scratch, and devised and implement new multi-business-line model for Novartis that covers innovative drugs, generic, OTC, and vaccine products.

Jun holds a Bachelor’s Degree in Clinical Medicine from the Capital University of Medical Sciences in China, and a MBA degree from Thunderbird School of Global Management in Phoenix, Arizona.

Roberta Lipson is CEO of Chindex International, and United Family Healthcare. She has 30 years of experience in the healthcare industry in China. Since she co-founded Chindex in 1981, the company has expanded from its business of capital medical equipment distribution to healthcare delivery. She is the creative force behind the United Family Healthcare brand, and its hospitals and clinics in Beijing, Shanghai, Tianjin, Guangzhou, Qingdao, Wuxi and Ulaanbaatar, the capital city of Mongolia.

United Family is the first foreign invested and managed private healthcare group in China. An active leader in the business community in Beijing, Ms. Lipson has served as a director of the U.S. China Business Council, as well as held 4 successive terms on the board of the Governors of the American Chamber of Commerce – China (AmCham) and is Co-Chair of the Amcham Healthcare Forum. She also chairs the Board of the United Foundation for China’s Health and is a co- founder of Kehilat Beijing. Ms. Lipson holds a BA from Brandeis University and an MBA from Columbia University.

Jie Qiao, reproductive medical doctor & biologic scientist, serves as the President of Peking University Third Hospital and Reproductive Medical Society of Chinese Medical Doctor Association. She is also the chairman for both National Clinical Research Center on Obstetrics and Gynecology Disease and Assisted Reproduction Key Laboratory, Ministry of Education. She went to Queen Mary Hospital, University of Hong Kong as a visiting scholar in 1996 and to Stanford University Medical Center as a Postdoctoral Research Scholar in 2003. Her interest focuses on the molecular mechanism of human gametogenesis and embryo development, infertility causes and clinical treatments. She has made outstanding contribution to transforming basic research to clinical application. Qiao built a research team combined with basic and clinical medicine, and established a series of prominent clinical research database. Her research reveals critical mechanisms of infertility and developmental regulation.

She has published 131 SCI papers as the first or corresponding author, including Cell, Nature, Lancet, etc.

Ms. Gilroy is a Senior Advisor to NYP Global Services and is a seasoned healthcare professional with over twenty years of diverse hospital development and operational management experience in the United States and abroad. Ms. Gilroy has assumed leadership roles on multiple international hospital development projects in various roles and participated in taking them from concept to delivery, including: University Hospital, an academic teaching hospital which was to be affiliated with Harvard Medical School Dubai Center (HMSDC) in Dubai, UAE; Shanghai Children’s Medical Center (SCMC), the pediatric center of choice in Shanghai, China, developed with the support of Project HOPE. In addition to her international and consulting experience, Ms. Gilroy has held senior healthcare management positions in New York, Boston, and Pennsylvania. Kathleen holds a Bachelor of Science Degree in Industrial Engineering and her Masters in International Business Administration and her particular areas of expertise include the operational change management, project management of start-up organizations and commissioning of international hospitals, and hospital operations in academic medical centers.

As the Director of UPMC International’s Advisory Services team, Mr. Collins manages the day to day operations of the UPMC’s international consulting team, which is integral to on-site assessments and program development projects across a range of medical specialties offering clients strategic direction in their pursuits.

During his career at UPMC, Mr. Collins has provided extensive project management, operational oversight, and consultative services in the development of the Xiangya International Medical Center in Changsha, China, the National Research Oncology Center and other Nazarbayev University Hospitals in Astana, Kazakhstan, the Center for Integrated Oncology at the University of Cologne, Germany, the Hospital Inernacional de Colombia in Bucamarunga, Colombia, and Medscan in Moscow, Russian Federation.

Recognizing the health care needs across different geographies, Mr. Collins is tasked with identifying new product line developments that suit customer needs and lend meaningfully to UPMC’s international business. Mr. Collins has also worked for UPMC’s Strategic Planning Department, focused on domestic-side, competitive market. Mr. Collins has both Bachelors and Masters of Science Degrees in Public Policy and Management from Carnegie Mellon University.

Board Healthcare is an excellent operating company invested
in private hospitals. It now has 3 subsidiaries: Yunnan Kidney
Hospital, Yunnan Boya Hospital and Kunming Mum & Me
Care Company.

Yunnan Kidney Hospital was founded in 1997 by the Yunnan
Health Bureau, the only Level 3 Kidney Specialty Hospital in
Yunnan, which owns 100 dialysis machines and 80 inpatient
beds. It is proud to be the first and the only private hospital to
achieve the “National Key Clinical Nephrology Specialty” in
Yunnan province in 2010.

Board Healthcare has invested 500 million RMB Yuan to build Yunnan Boya Hospital,
which is completed in June 2015 and meets Level 3 General Hospital Certification.
The hospital has 500 inpatient beds and is 60 thousand square-meters in area. It
focuses on Cardiology, Nephrology, Ob/Gyn and Healthcare Management. The
hospital has been the most promising and largest investment in recent times,
becoming the largest private hospital in Yunnan.

Shenbo, as the leader who specializes in professional knowledge and skills regarding
medical and management, spent years on investment construction and operation
management. He has extensive experience in establishing hospital institutions,
positioning healthcare markets and developing business strategy.
Shenbo has a depth of knowledge when it relates to the use of information technology
to enhance the operational efficiency of private hospitals. He also has strength in
managing medical safety, especially since he has a unique view on information
process reengineering. He has also designed and developed a Hemodialysis
Information Management System, which has received praise by medical experts.

Sun Qiyin is Board Chairman of Top Grade Healthcare based in Beijing and Board Executive
Director of Soochow University and Chairman of the Affiliated Cancer Hospital of Soochow
University in Jiangsu Province since the year 2000. After years of research in medical field, he, as
the Board Chairman, leads his team of Top Grade Healthcare developed and manufactured
equipments of PET、PET-CT、PET-MR and A45 and developed new technology of A45 Treatment
for cancer, vascular plaques and other diseases.

At the very early stage of his career, Mr. Sun Qiyin matured as a doctor in hospital with rich
clinical experience and hospital management. During Sept. 1990-Mar. 2000, he was the General
Manager of Wanjie Group. As the founder, he was also the President of Wanjie Hospital-the first
domestic joint venture comprehensive hospital. It was him who the first time introduce hi-tech
medical equipments to China like proton MM50, gamma knife, PET, PET-CT, X-ray knife, photon
knife, and Novalis.

Up to now, Mr. Sun Qiyin has written 3 monographs as lead author: MRI Diagnostics,
Exploration of Establishment and Assessment of Medical Services Quality System, New Progress
of Coronary Heart Disease Treatment, and has published over 30 medical research theses

Li Yadong is currently the General Manager of Intel’s Healthcare and Life Sciences Group in the Asia Pacific Area. He is responsible for formulating strategy, business development and technology cooperation in the region.

In 2005, Li Yadong became Project Manager and Engineering Manager for Intel Asia-Pacific R&D Co., Ltd. Channel Platforms Group. He was responsible for PC innovations, product R&D and project management in emerging markets. He also was in charge of project management in India’s Village Computer Program, exploring the market for student computer products and laptop computer design and promotion. Since becoming the General Manager of PCCG in China in 2011, his team has earned the most prestigious Intel award: IAA. In 2013 he was selected for Intel’s Accelerated Leadership Development Program, and was rotated to the US to work in various Market Strategy Departments for one-and-a-half years. In 2014 he joined the Healthcare and Life Sciences Group (HLS) in US, and in 2015 he returned to China to become the HLS Program Director for the Asia Pacific Area. In 2016, Li Yadong was promoted to the position of General Manager of Intel’s Healthcare and Life Sciences Group in Asia Pacific Area.
Li Yadong graduated from the University of Electronic Science and Technology of China in 1996. In 2001 he graduated from Shanghai Jiao Tong University with a Master’s Degree in Industrial Engineering. In 2009 he graduated from the University of Southern California with a Master’s Degree in Business Management.

James is responsible for developing market access strategies and programs to ensure appropriate development of new and existing technologies for the company, he also establishes PR & communication strategies to build and manage external relationships with key players from academia and the general public.

James has worked for multinational healthcare companies, in both the pharmaceutical and medical device industries, in China for more than 20 years. He was co-chair of the AmCham Shanghai Healthcare committee from 2012-2014.

James holds a Bachelors of Medicine Degree from Fudan University Medical Institute, and an MBA training from the Insead Institute of Industrial & Commercial.

The mission of the Medtronic Diabetes Service and Solutions business is to offer people with diabetes access to therapy, insight and services that contribute to better clinical outcomes and economic value – today and tomorrow.

Maxine Lu has worked in diabetes industry for 10 years. In recent 6 years with Medtronic, Maxine has extensive experience in strategic marketing, customer service, patient education, and direct-to-consumer marketing, developing strategies to expand access of physicians, patients and their families in China to Medtronic’s diabetes therapies. Prior to joining Medtronic, Maxine led professional education at Johnson & Johnson Medical China, where she developed series programs and partnered with China Diabetes Society and Ministry of Health in China to improve doctors and nurses skills and knowledge of diabetes management. She also had 6 years cross-industry experience in telecommunication of fortune 500 companies.

Maxine has a full-time MBA degree from McCombs School of Business in University of Texas at Austin. She is fluent in English, native speaker of Mandarin and Cantonese.

Assistant President and Head of Business Development in Simcere Pharmaceutical Group. Since Dr. Wang joined Simcere in2006, he has held a variety of positions of increasing responsibility at Simcere, including the leader of formulation R&D, program group director for the development of all generic drugs, and BD Director. Under his leadership, Simcere BD team has successfully initiated dozens of generic projects, as well as many licensing in/out co-development programs.
Dr. Wang holds a B.S. in Pharmaceutical Engineering, an M.S. in Pharmaceutics from Fudan University in Shanghai and a Ph.D. in Pharmaceutics from China Pharmaceutical University. He is a Certified Project Management Professional.

Jennifer is a Independent Content Producer, Filmmaker, Freelance Journalist and Breast Cancer Survivor based in Beijing China. She focuses on developing writing and producing original, inspirational, entertaining contents that build a human connection with her audience. She’s also Beijing Correspondent for Press TV - a English Speaking News Channel broadcasting news to the World 24/7. She has produced international advertising campaigns for brands including Volkswagen, BMW, Mercedes Benz, Intel and Dell.

Besides producing entertainment content, Jennifer also believes media and films can be a strong force in social change. She started a Public Awareness – “Love is Blind” Campaign with Bethel China and her creative friends, helping raise awareness for orphaned special needs children's education and adoption. She's currently working on a feature length documentary - "Blind Pursuit Of A Dream" for special needs children education.

Zhang Fuquan is Director of Department of Radiotherapy; Chief physician; Professor; Doctoral supervisor, Peking Union Medical College Hospital
Professor Zhang is the director of the radiotherapy Department in Peking Union Medical College Hospital, graduated from Norman Bethune University of Medical Sciences. He works as Committee member of Radiation oncology Therapeutics branch of Chinese Medical Association, Vice Chairman of the Radiation Oncology Branch of the Medical Association in Beijing, Vice President of Radiotherapy Committee of Beijing physicians Association and Director of the radiotherapy quality control center in Beijing. He also works as the editorial board both in Chinese Journal of Radiation Oncology and Chinese Journal of Oncology.

Godfrey Firth is the National Sales Director, Global Investments for GE Healthcare China, responsible for strategic partnerships with global healthcare partners working in China, including all foreign-invested hospital and healthcare provider accounts He also concurrently serves as the Director of Government Affairs and Policy, China for GE Healthcare China. responsible for government affairs strategy, policy advocacy and collaborative programs with government agencies.
Godfrey also serves on the Steering Committee of the US-China Healthcare Cooperation Program under AmCham China and is the Vice-Chair of the European Chamber in China Healthcare Equipment Working Group.
Godfrey joined GE in 2009 from the US-China Business Council (USCBC), where he served as Chief Representative, Shanghai from 2006-2009. Before the USCBC, Godfrey worked in Chengdu for the International Finance Corp., part of the World Bank Group. Godfrey has also worked in the market research industry in China, and has been resident here since 2000.

Godfrey holds a bachelor’s degree in history and international relations from Boston University, and a master’s in regional studies – East Asia from Harvard University.

Dr. Yi-Xin Zeng received his doctor degree from Sun Yat-sen University of Medical Sciences in 1990. He studied molecular mechanisms of cancer pathogenesis in Tokyo Metropolitan Institute of Gerontology, Tokyo University and University of Pennsylvania from 1992 to 1997. He was appointed as a professor of Sun Yat-sen University of Medical Sciences and vice president of Sun Yat-sen University Cancer Center after he returned to China in 1997. He had been the president of Sun Yat-sen University Cancer Center since 1997 till 2011. He has served as the Director of State Key Laboratory of Oncology in South China since 2004. Now he is a professor and president of Peking Union Medical College. Dr Yi-Xin Zeng is currently leading the 863 program (National High Technology Research and Development Program of China) “Molecular Classification and Personalized Therapy for Major Diseases” and 973 program (National Basic Research Program of China) “Research on Mechanisms and Intervene of Oncogenic Virus”. He was elected as Outstanding Young Teacher by Ministry of Education in 2002, Outstanding Young Expert by Ministry of Health in 2006. His research is devoted to the pathogenesis of cancer and cancer biotherapy, with a focus on nasopharyngeal carcinoma (NPC) and Epstein-Barr virus (EBV), on which he has published over 300 papers. He has been honoured many awards for his research, including Second Class Award for Natural Science Achievements (National Office for Science and Technology Awards, 2005), He-Liang-He-Li Award for Science and Technology Advancement (2007), Award for Outstanding Science and Technology Achievements in Guangdong Province (the People's Government of Guangdong Province, 2011). He served as the president of International Association of EB Virus and Related Diseases from 2006 to 2008. He is now the Chief Editor of Chinese Journal of Cancer and the text book “Oncology”. He has also acted as the vice president of China Anti-Cancer Association since 2007. He also serves as Adjunct Professor in Karolinska Institute, Hongkong University and Macao University of Science and Technology.

Daotian Fu is Vice President of Livzon Pharmaceutical Group. He is also General Manager of Livzon MabPharm, Inc., which is an early stage biologics development company. Prior to joining Livzon in May 2012, Daotian was Vice President at Genzyme, where he was responsible for the quality control and analytical development of all biologics in development. He worked for Genzyme for over 12 years. Prior to joining Genzyme, he also held several technical and management positions, including Director at Charles River Lab and Manager of Neose Pharmaceuticals. Daotian Fu received his BS from Shandong University in China, and his Ph.D. from Iowa State University. He also received post-doctoral training at University of Georgia in collaboration with Harvard Medical School. Daotian is the recipient of the National “1000 Talent” program.

Dr. Zhi-Cheng Jin is a Professor of Medicine at Tongji University School of Medicine in Shanghai. He currently holds the Ministry of Education’s Yangtze River Scholars Distinguished Professorship title, is President of the Thrombosis and Hemotosis Society of Beijing, and is active in the scientific research community. In 2015 he was awarded the Grand Challenges Young Scientist award, which is given by the Ministry of Science and the Bill and Melinda Gates Foundation, and was nominated for “Beijing’s Top Ten Doctors” award.

He has also held top positions among a collection of respected international medical journals, including roles as the Deputy Chief Editor of the Chinese Medical Journal, editorial Board Member of the European Respiratory Journal, Editorial Board Member of the Chinese Journal of Cardiology, and Associate Editor of the Annals of American Thoracic Society. In addition to these roles, he has also led numerous novel scientific studies on pulmonary cardiovascular disease.

Dr. Jing has over two decades of experience in medicine, and received Post-Doctoral Fellow training at the National Center for Pulmonary Vascular Disease at Antoine Beclere Hospital of University Paris-Sud in France.

Dr. Qin graduated from Tongji Medical University with a bachelor's degree and completed her PhD at Bucharest Carol Davila University of Medicine and Pharmacy in Romania. Dr. Qin served as rheumatologist in Bucharest Sf. Maria Hospital and Beijing Xuanwu hospital, Medical Manager of Hospitality center of Beijing Olympic Committee, Influenza and Disaster Management Coordination officer of United Nations Development Program in China. She has 20 years clinical experience in Internal Medicine, Rheumatology and Geriatrics. Dr. Qin together with her medical team is devoted to provide individualized continuous medical care with high quality.

Wang Guangfa is Head of Respiration Medicine and a Chief Physician at the Peking University First Hospital, specializing in the diagnosis and treatment of the respiratory system. Wang Guangfa received his Bachelor’s Degree and Graduate work at the Beijing Medical University, completing on the job Post graduate studies at Peking Health Science Center advanced studies at Jichi Medical University in Japan. Wang Guangfa has nearly 20 years of experience at PUFH, is a Senior Member and Governor of China Region of American College of Chest Physicians, and holds a number of positions in medical associations and journals. He has also received numerous rewards, including the Second Prize of Scientific-Technical Progress of Beijing in 2005.

Dr. Zhu is from China. He completed his medical degree at Shanghai Medical University, and he completed his master’s degree in Surgery at Peking Union Medical College (PUMC). He completed his PhD degree and post-doctoral clinical research fellowship at King’s College London, U.K.

Dr. Zhu started his career in the Beijing Hospital of the Ministry of Health. After returning from the U.K., he returned to the Beijing Hospital as a urological specialist and, later, as a urology consultant and professor of Urology. He is an international pioneer in single port laparoscopic surgery techniques. He has been involved in over 20 international and national academic societies and has more than 23 years of experience in the field of Urology.

Dr. Zhu’s clinical interest is mainly focused on Urological Oncology and prostate diseases, and in particular on prostate cancer management and minimally invasive surgery. He has published 63 peer-reviewed papers in both national and international medical journals and contributed to eight books.

Dr. Zhu speaks English and Mandarin.